Biogen stock sinks after Alzheimer's drug trial data fails to impress investors

Biogen's stock declined following the release of Alzheimer's drug trial data that failed to meet its primary goal. The study showed the drug's lowest dose outperformed higher doses in ways the company cannot yet explain.